shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 13; no. 11; pp. 5865 - 5869
• Main Authors: Ghafouri-Fard, Soudeh, Abdollahi, Davood Zare, Omrani, Mirdavood, Azizi, Faezeh
• Format: Journal Article
• Language: English
• Published: Thailand 01.01.2012
• Subjects: Apoptosis; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Caspase 8 - genetics; Caspase 8 - metabolism; Cell Proliferation; Female; Gene Silencing; Homeodomain Proteins - antagonists & inhibitors; Homeodomain Proteins - genetics; Homeodomain Proteins - metabolism; Humans; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Small Interfering - genetics; Transfection; Tumor Cells, Cultured
• ISSN: 1513-7368; 2476-762X
• DOI: 10.7314/APJCP.2012.13.11.5865

RHOXF1 has been shown to be expressed in embryonic stem cells, adult germline stem cells and some cancer lines. It has been proposed as a candidate gene to encode transcription factors regulating downstream genes in the human testis with antiapoptotic effects. Its expression in cancer cell lines has implied a similar role in the process of tumorigenesis. The human breast cancer cell lines MDA-MB-231 and MCF-7 were cultured in DMEM medium and transfected with a pGFP-V-RS plasmid bearing an RHOXF1 specific shRNA. Quantitative real- time RT-PCR was performed for RHOXF1, CASP8, BCL2 and HPRT genes. Decreased RHOXF1 expression was confirmed in cells after transfection. shRNA knock down of RHOXF1 resulted in significantly decreased BCL2 expression in both cell lines but no change in CASP8 expression. shRNA targeting RHOXF1 was shown to specifically mediate RHOXF1 gene silencing, so RHOXF1 can mediate transcriptional activation of the BCL2 in cancers and may render tumor cells resistant to apoptotic cell death induced by anticancer therapy. shRNA mediated knock down of RHOXF1 can be effective in induction of apoptotic pathway in cancer cells via BCL2 downregulation, so it can have potential therapeutic utility for human breast cancer.